Skip to main content
Equibles
PACS logo

PACS · PACS Group, Inc.

Track PACS — free

Use PACS with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about PACS

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$44.44 -0.55 (-1.22%) At close · Aug 14
Market Cap
$7.04B
Shares
158.34M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$44.44 Open$44.00 Day$43.77–44.97 52W close$7.71–48.45 Avg vol 30d908K Short int3.8M · 2.4% float · 4.7d Short vol51% Last earningsAug 5, 2026 DataApr 2024–Aug 2026 Filing10-Q · Aug 4

Up next

Next earnings call
Nov 5, 2026 Est · unconfirmed · in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 4, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Buy
      SellHoldBuy
      Technical Buy Momentum Neutral Sentiment Bullish Fundamentals Excellent Quant / Vol Very High
      Market backdrop VIX 14.3 · calm Equity put/call 0.52
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +25%
      above
      Price vs 50-day avg +5%
      above
      RSI (14) 48
      neutral
      MACD trend Negative
      52-week position 90%
      near high
      Volume (OBV) Bullish div.
      accumulating
      Momentum
      relative strength
      Neutral
      1-month return −4%
      trailing
      6-month return +9%
      trailing
      YTD return +16%
      this year
      Relative strength −5%
      vs S&P · 6-mo
      Sentiment
      smart money
      Bullish
      Trend (MA cross) No cross
      50d $43 › 200d $35 — 50d above 200d
      Institutional flow Accumulating
      +8% holders QoQ · +56 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      2.41% of float · ▼ -15.6% MoM · 4.7 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      237 holders — near 2-yr high, broad support
      Squeeze score 53
      elevated · 0–100
      Fundamentals
      Excellent
      Revenue growth +29%
      Y/Y
      EPS growth +221%
      Y/Y
      Buyback $250.0M
      remaining
      Balance sheet $52.3M
      net debt
      Quant / Vol
      risk profile
      Very High
      Volatility 102%
      annualized · 1-yr
      Max drawdown −36%
      past year
      ATR 5.6%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Latest guidance · from the 8-K filed Aug 4, 2026
      Revenue · full-year 2026 $5.75B – $5.85B
      Prior guidance period ended · from the 8-K filed Nov 19, 2025
      Revenue · full year 2025 $5.25B – $5.35B
      Adjusted EBITDA · full year 2025 $480M – $490M
      Guided vs delivered · last 1 settled
      Revenue full year 2025
      guided $5.25B – $5.35B
      $5.29B In line

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Buy
      1 · 2 · 4
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +25% Bullish
      Price vs 50-day avg
      +5% Bullish
      RSI (14)
      48 Neutral
      MACD trend
      Negative Bearish
      52-week position
      90% Bullish
      Volume (OBV)
      Bullish div. Bullish
      Market signals — smart money & positioning
      Bullish · 3 of 6
      Trend (MA cross) No cross
      50d $43 › 200d $35 — 50d above 200d
      Institutional flow Accumulating
      +8% holders QoQ · +56 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      2.41% of float · ▼ -15.6% MoM · 4.7 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      237 holders — near 2-yr high, broad support
      Price context
      position in its 52-week range
      Range low $8 Now $44 · 90% Range high $48
      vs 200-day avg +25% vs 50-day avg +5%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      GAAP → non-GAAP reconciliation
      GAAP EBITDA 132.02M
      +734K Acquisition related costs
      +25.83M Stock-based compensation expense
      +8.17M Legal and other costs
      = Adjusted EBITDA 166.75M
      GAAP → non-GAAP reconciliation
      GAAP Adjusted EBITDA 166.75M
      +94.7M Rent - cost of services
      = Adjusted EBITDAR 261.45M
      Available liquidity $756.6M As of June 30, 2026 —
      Healthcare operations (portfolio) 344 As of August 1, 2026 —
      Leased facilities with partial ownership in real estate 49 As of August 1, 2026 —
      Mature facilities CMS Quality Measure Star rating (average) 4.5 Q2 2026 —
      Mature facilities skilled mix 31.9% Q2 2026 —
      Number of facilities with 4 or 5 star CMS Quality Measure Star rating 239 Q2 2026 —
      Owned facilities 64 As of August 1, 2026 —
      Patients served daily 33,400 As of August 4, 2026 —
      Purchase options on leased facilities 36 As of August 1, 2026 —
      Purchase options through partnerships 20 As of August 1, 2026 —
      Same-store SNF revenue growth 5.8% Q2 2026 —
      Facilities achieving 4 or 5 star CMS Quality Measure Star rating 222 first quarter of 2026 —
      Ramping facilities occupancy 88.9% first quarter of 2026 —
      Share repurchase authorization $250M first quarter of 2026 —
      Assisted living beds added 271 Full Year 2025 —
      Number of facilities at period end (Mature) 149 Year ended December 31, 2025 —
      Number of facilities at period end (New) 78 Year ended December 31, 2025 —
      Number of facilities at period end (Ramping) 64 Year ended December 31, 2025 —
      Number of facilities at period end (Total) 291 Year ended December 31, 2025 —
      Number of operating facilities added 8 Full Year 2025 —
      Number of operational beds at period end (Mature) 16,415 Year ended December 31, 2025 —
      Number of operational beds at period end (New) 8,153 Year ended December 31, 2025 —
      Number of operational beds at period end (Ramping) 8,286 Year ended December 31, 2025 —
      Number of operational beds at period end (Total) 32,854 Year ended December 31, 2025 —
      Occupancy rate (operational beds) - Mature 94.9% Year ended December 31, 2025 —
      Occupancy rate (operational beds) - Total 89.1% Year ended December 31, 2025 —
      Skilled mix by nursing days - Total 28.7% Year ended December 31, 2025 —
      Skilled mix by nursing revenue - Total 48.8% Year ended December 31, 2025 —
      Skilled nursing beds added 655 Full Year 2025 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Medical Care Facilities — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      PACS
      PACS Group, Inc.
      this stock
      		$7.04B +15.8% +29.3% — 2.4%
      HCA
      HCA Healthcare, Inc.
      		 $89.77B -13.3% +7.1% 13.9 2.7%
      FSNUY
      Fresenius SE & Co. KGaA
      		 $30.87B -4.4% — — 0.0%
      THC
      Tenet Healthcare Corp
      		 $21.57B +34.8% +0.9% 10.3 4.0%
      FMS
      Fresenius Medical Care AG
      		 $12.65B -0.2% +5.9% — 0.5%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      237
      % held
      32.3%
      Net QoQ
      +2.9M sh
      Top holder
      COHEN & STEERS, INC.
      Held Float
      View
      Held by Funds
      Fund positions
      264
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      3.8M
      Days to cover
      4.7d
      Change
      -705.4K sh
      View
      Short Volume
      Short vol %
      51%
      As of
      Aug 14, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      143
      Value
      $6.3K
      As of
      Jul 9, 2026
      View
      Off-Exchange
      Off-exchange %
      45.1%
      Week of
      Jul 6, 2026
      Off-exch Lit
      View
      Financials
      Financials
      Revenue (FY)
      $5.3B
      Net income (FY)
      $191.5M
      EPS diluted
      $1.22
      View
      Buybacks
      Authorized
      $250.0M
      Remaining
      $250.0M
      Spent Remaining
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 4, 2026
      This year
      10
      View
      Proposed Sales
      Value
      $150.1K
      Shares
      3.3K
      Filed
      Jul 15, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 5, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      PACS -8.3% -3.7% +8.9% -3.4% +15.8%
      SPY +0.4% +4.5% +13.8% +3.9% +13.9%
      vs SPY -8.7% -8.1% -4.9% -7.3% +1.9%

      Capital returns

      Buyback program · as of Jun 30, 2026
      Authorized
      $250.00M
      Spent (derived)
      $0
      Remaining
      $250.00M
      Spent Remaining

      Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

      Key facts CIK 2001184 CUSIP 69380Q107 13F (30d) 223 filings 221 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)